The role of hypoxia-inducible factors in neovascular age-related macular degeneration: a gene therapy perspective
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1420-9071
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The role of hypoxia-inducible factors in neovascular age-related macular degeneration: a gene therapy perspective ; volume:77 ; number:5 ; day:31 ; month:12 ; year:2019 ; pages:819-833 ; date:3.2020
Cellular and molecular life sciences ; 77, Heft 5 (31.12.2019), 819-833, 3.2020
- Creator
-
Mammadzada, Parviz
Corredoira, Pablo M.
André, Helder
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00018-019-03422-9
- URN
-
urn:nbn:de:101:1-2020052520102132311382
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mammadzada, Parviz
- Corredoira, Pablo M.
- André, Helder
- SpringerLink (Online service)
Other Objects (12)
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
Vision protection therapy for prevention of neovascular age-related macular degeneration
Efficacy and safety of abicipar in neovascular age-related macular degeneration
Treatment of age-related neovascular macular degeneration: the patient’s perspective
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Influence of new societal factors on neovascular age-related macular degeneration outcomes
Pigment epithelial detachment composition indices (PEDCI) in neovascular age-related macular degeneration
Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
Vision protection therapy for prevention of neovascular age-related macular degeneration
Efficacy and safety of abicipar in neovascular age-related macular degeneration
Treatment of age-related neovascular macular degeneration: the patient’s perspective
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Influence of new societal factors on neovascular age-related macular degeneration outcomes
Pigment epithelial detachment composition indices (PEDCI) in neovascular age-related macular degeneration
Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration
Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
Vision protection therapy for prevention of neovascular age-related macular degeneration
Efficacy and safety of abicipar in neovascular age-related macular degeneration
Treatment of age-related neovascular macular degeneration: the patient’s perspective
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Influence of new societal factors on neovascular age-related macular degeneration outcomes
Pigment epithelial detachment composition indices (PEDCI) in neovascular age-related macular degeneration
Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration